In vitro activity of telavancin compared with vancomycin and linezolid against gram-positive organisms isolated from cancer patients

Journal of Antibiotics

Volumn 67, Issue 7, 2014, Pages 505-509

  Rolston, Kenneth Vi ^a,b   Wang, Weiqun ^b   Nesher, Lior ^a   Coyle, Elizabeth ^a,b   Shelburne, Samuel ^a   Prince, Randall A ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

cancer patient; Gram positive; linezolid; telavancin; vancomycin

Indexed keywords

ACETAMIDES; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; NEOPLASMS; OXAZOLIDINONES; VANCOMYCIN;

EID: 84904977202     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2014.30     Document Type: Article

References (30)

1. Klastersky, J. et al. Bacteraemia in febrile neutropenic cancer patients. Int. J. Antimicrob. Agents. 30 (Suppl 1), S51-S59 (2007).
2. Montassier, E., Batard, E., Gastinne, T., Potel, G. & de La Cochetiere, M. F. Recent changes in bacteremia in patients with cancer: A systematic review of epidemiology and antibiotic resistance. Eur. J. Clin. Microbiol. Infect. Dis. 32, 841-850 (2013).
3. Han, X. Y., Kamana, M. & Rolston, K. V. Viridans streptococci isolated by culture from blood of cancer patients: Clinical and microbiologic analysis of 50 cases. J. Clin. Microbiol. 44, 160-165 (2006). (Pubitemid 43100595)
4. Shelburne, S. A. 3rd, Tarrand, J. & Rolston, K. V. Review of streptococcal bloodstream infections at a comprehensive cancer care center, 2000-2011. J. Infect. 66, 136-146 (2013).
5. Moellering, R. C. Jr. Vancomycin: A 50-year reassessment. Clin. Infect. Dis. 42 (Suppl 1), S3-S4 (2006).
6. Freifeld, A. G. et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin. Infect. Dis. 52, e56-e93 (2011).
7. Steinkraus, G., White, R. & Friedrich, L. Vancomycin MIC creep in non-vancomycinintermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60, 788-794 (2007). (Pubitemid 47434257)
8. Safdar, A. & Rolston, K. V. Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer. Cancer 106, 1815-1820 (2006).
9. Pillai, S. K. et al. Development of reduced vancomycin susceptibility in methicillinsusceptible Staphylococcus aureus. Clin. Infect. Dis. 49, 1169-1174 (2009).
10. Sakoulas, G. et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42, 2398-2402 (2004). (Pubitemid 38747480)
11. CLSI. Performance Standards for antimicrobial susceptibility testing. CLSI approved standard M100-S20 (CLSI, Wayne, PA, USA, 2010).
12. van Hal, S. J., Lodise, T. P. & Paterson, D. L. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: A systematic review and meta-analysis. Clin. Infect. Dis. 54, 755-771 (2012).
13. Hsu, D. I. et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents. 32, 378-385 (2008).
14. Liu, C. et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: Executive summary. Clin. Infect. Dis. 52, 285-292 (2011).
15. Hope, R., Chaudhry, A., Adkin, R. & Livermore, D. M. In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci. Int. J. Antimicrob. Agents. 41, 213-217 (2013).
16. Mendes, R. E., Sader, H. S., Farrell, D. J. & Jones, R. N. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents. Antimicrob. Agents. Chemother. 56, 3999-4004 (2012).
17. Rolston, K. V., Kapadia, M., Tarrand, J., Coyle, E. & Prince, R. A. Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients. Int. J. Antimicrob. Agents. 41, 516-520 (2013).
18. Hughes, W. T. et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 34, 730-751 (2002). (Pubitemid 34194843)
19. Finberg, R. W. et al. The importance of bactericidal drugs: Future directions in infectious disease. Clin. Infect. Dis. 39, 1314-1320 (2004). (Pubitemid 39458517)
20. Mahajan, S. N. et al. Characteristics and outcomes of methicillin-resistant staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center. Oncologist 17, 1329-1336 (2012).
21. Gu, B., Kelesidis, T., Tsiodras, S., Hindler, J. & Humphries, R. M. The emerging problem of linezolid-resistant Staphylococcus. J. Antimicrob. Chemother. 68, 4-11 (2013).
22. Mendes, R. E., Sader, H. S., Farrell, D. J. & Jones, R. N. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009). Diagn. Microbiol. Infect. Dis. 72, 113-117 (2012).
23. Mendes, R. E., Sader, H. S., Farrell, D. J. & Jones, R. N. Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010). Diagn. Microbiol. Infect. Dis. 71, 93-97 (2011).
24. Klotchko, A., Wallace, M. R., Licitra, C. & Sieger, B. Staphylococcus lugdunensis: An emerging pathogen. South. Med. J. 104, 509-514 (2011).
25. Smith, K., Gemmell, C. G. & Lang, S. Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models. Eur. J. Clin. Microbiol. Infect. Dis. 32, 1327-1332 (2013).
26. Pankey, G. A. & Ashcraft, D. S. In Vitro Synergy of telavancin and rifampin against enterococcus faecium resistant to both linezolid and vancomycin. Ochsner J. 13, 61-65 (2013).
27. Stryjewski, M. E. et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin. Infect. Dis. 46, 1683-1693 (2008). (Pubitemid 351706765)
28. Rubinstein, E. et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin. Infect. Dis. 52, 31-40 (2011).
29. Hegde, S. S., Difuntorum, S., Skinner, R., Trumbull, J. & Krause, K. M. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. J. Antimicrob. Chemother. 63, 763-766 (2009).
30. Reyes, N. et al. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58, 462-465 (2006). (Pubitemid 44294968)